Selmani, Zohair
Molimard, Chloé
Overs, Alexis
Bazan, Fernando
Chaigneau, Loic
Dobi, Erion
Meneveau, Nathalie
Mansi, Laura
Paillard, Marie-Justine
Meynard, Guillaume
Viot, Julien
Algros, Marie-Paule
Borg, Christophe
Feugeas, Jean-Paul
Pivot, Xavier
Prétet, Jean-Luc
Curtit, Elsa
Article History
Received: 1 July 2021
Accepted: 16 February 2022
First Online: 7 March 2022
Competing interests
: ZS: Honoraria from Pfizer, Genomic Health EC: Honoraria from Novartis, Pfizer, Daiichi, Genomic Health FB: Honoraria from Roche, Novartis, Pfizer, Astra-Zeneca, Clovis, Daiichi. CB: advisory board from Bayer, BMS, msd, servier and research grant from Roche NM, JV, CM, AO, JLP, JPF, ED, LM, MPA, LC, MJP, GM, XP: have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.